24Jan
24Jan
Akston Biosciences Strengthens Board with Addition of John T. Preston
Akston Biosciences Corporation, a clinical-stage biotechnology company, today announced that John T. Preston, a founder of TEM Capital, has joined its Board of Directors. A recipient of numerous awards and previous advisor to several government agencies and expert witness for Congress, Preston brings to Akston his decades of experience in technology commercialization and intellectual property licensing. Preston spent most of his career at the Massachusetts Institute of Technology (MIT), managing the interface between researchers and industry. His titles included Associate...
23Jan
So Long Mic!
Ziad Moukheiber, Boston Harbor Angels and the angel investing community are sad to announce that Mic Williams took his last ride into the sunset. Mic was the Founder of Boston Harbor Angels, a leading angel investing group in the Boston area and a pioneer in angel investing. As an early member of the Angel Capital Association, Mic was a pillar of the community. Lucky are the ones who had the opportunity to have a drink with Mic and the ACA regulars,...
20Jan
OmniLife Health’s Clinical Workflow Automation Platform Enhances Capabilities Within Organ Transplant, Expands into Complex Healthcare Environments
OmniLife Health, a leader in clinical workflow automation enabling healthcare teams to improve outcomes, enhance efficiencies, reduce costs and improve revenue capture, has expanded its FlowHawk™ platform into additional complex healthcare environments. First developed as a HIPAA-compliant messaging solution for transplant teams, FlowHawk has evolved into an end-to-end platform that automates clinical workflows for organ transplant, organ failure care, oncology, and complex care verticals. FlowHawk’s expansion is timely; a Becker’s Healthcare survey commissioned by OmniLife Health showed adoption of clinical...
20Jan
VentureSouth invested $12M in 34 companies in 2022
VentureSouth, one of the Top 10 angel investment groups in North America, provided $12 million in capital investment to 34 companies in 2022, the organization announced Jan. 17. VentureSouth also made additional investments in nearly two dozen existing portfolio companies, including: Zylo Therapeutics. n November 2022, the organization announced it planned to partner with the investor group 757 Angels. The partnership, which will bring 757 Angels into VentureSouth’s network in June, is the angel investment group’s second market in Virginia...
20Jan
How Pixability is helping brands monitor YouTube and CTV campaigns for safety, performance and suitability
Pixability, a software and insights platform, is one company helping brands and agencies ensure brand-safe ads on YouTube and CTV while also taking campaign performance and audience makeup into account. Pixability’s CPO, Jackie Paulino, recently spoke with Mike Shields, co-founder of Marketecture Media and host of the ‘Next in Marketing’ podcast, about how brands are using video advertising platforms to improve campaign performance and ensure they align with brand values. Read more >>
20Jan
Watch Cocaine Bear’s Elizabeth Banks Try Tom Hanks’ Diet Coke And Champagne Cocktail ‘Diet Cokagne’
M3GAN has been taking the horror world by storm this month, so much so that M3GAN 2.0 is already in the works. However, come next month, there’ll be a new menace to entertain moviegoers, because Cocaine Bear is coming. Elizabeth Banks directed the upcoming horror movie, and ahead of its release, she’s getting some early promotion in by drinking a unique cocktail created by fellow actor Tom Hanks: a blend of Diet Coke and champagne, or “Diet Cokagne.” See what...
19Jan
RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial
RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University “G.D'Annunzio” of Chieti-Pescara to start a 15-patient pilot clinical trial. The primary objective of this study will be to assess the time it takes for Tetranite®, the company’s adhesive biomaterial, to regenerate bone in the mandibular and maxillary dental arches. This study will be conducted at the Center for Advanced Studies and Technology (“CAST”) of the University “G.d’Annunzio” Chieti-Pescara...
18Jan
Myomo Announces Closing of $6.5 Million Upsized Public Offering
Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses. Read more >>
17Jan